Get the Stockscreener App
50.00
0.79%
0.39
Pre-market:
56.38
6.38
+12.76%
Terns Pharmaceuticals Inc stock is traded at $50.00, with a volume of 2.42M.
It is up +0.79% in the last 24 hours and up +20.63% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$49.61
Open:
$49.22
24h Volume:
2.42M
Relative Volume:
1.07
Market Cap:
$5.44B
Revenue:
-
Net Income/Loss:
$-94.44M
P/E Ratio:
-48.45
EPS:
-1.032
Net Cash Flow:
$-77.99M
1W Performance:
+7.60%
1M Performance:
+20.63%
6M Performance:
+535.32%
1Y Performance:
+1,325%
1-Day Range:
$48.14
$50.37
1-Week Range:
$45.05
$50.89
52-Week Range:
$1.865
$50.89
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
50.00 | 5.44B | 0 | -94.44M | -77.99M | -1.032 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Leerink Partners | Outperform |
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Merck (MRK) Nears $6 Billion Acquisition of Terns Pharmaceuticals (TERN) - GuruFocus
Merck close to $6B acquisition of Terns Pharma to boost cancer portfolio: FT (MRK:NYSE) - Seeking Alpha
Merck nears $6 bln deal for Terns Pharma, FT reports By Investing.com - Investing.com Canada
Merck Nears Deal to Buy Terns Pharmaceuticals - Bloomberg.com
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports - marketscreener.com
According to insiders, merger negotiations between Merck (MRK) and Terns Pharmaceuticals, Inc. (TERN) have entered a critical stage. - Bitget
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports - marketscreener.com
Acorn Capital Sells $5.2M in Terns Pharma Shares, Remains Top Holding | 2026 UpdateNews and Statistics - IndexBox
Terns Pharmaceuticals (NASDAQ:TERN) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Terns Pharmaceuticals (NASDAQ:TERN) Sets New 12-Month HighShould You Buy? - MarketBeat
TERN Stock Chart | TERNS PHARMACEUTICALS INC (NASDAQ:TERN) - ChartMill
Aug PreEarnings: What is the target price for Terns Pharmaceuticals Inc stockShare Buyback & Stepwise Trade Execution Plans - baoquankhu1.vn
Terns Pharmaceuticals stock hits all-time high at 48.27 USD By Investing.com - Investing.com Australia
Terns Pharmaceuticals stock hits all-time high at 48.27 USD - Investing.com
How Vestal Point’s Big Bet On TERN-701 At Terns Pharmaceuticals (TERN) Has Changed Its Investment Story - Yahoo Finance
Aug Setups: What is the target price for Terns Pharmaceuticals Inc stockWall Street Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Superstring Capital Reduces Terns Pharmaceuticals Holding in Late 2025News and Statistics - IndexBox
Terns Pharmaceuticals CEO Burroughs sells $681k in stock By Investing.com - Investing.com Canada
Terns Pharmaceuticals CEO Burroughs sells $681k in stock - Investing.com
Amy Burroughs Sells 14,583 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock - MarketBeat
Terns Pharmaceuticals CEO Amy L. Burroughs Sells Shares - TradingView
Terns Pharmaceuticals (NASDAQ: TERN) CEO sells exercised shares under plan - Stock Titan
Vestal Point Capital's Major Investment in Terns Pharma | 2026News and Statistics - IndexBox
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally - The Globe and Mail
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia - Bitget
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - The Globe and Mail
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Terns Pharmaceuticals (TERN) Is Up 8.6% After Pipeline Update And Index Inclusion News - simplywall.st
5,700,000 Shares in Terns Pharmaceuticals, Inc. $TERN Acquired by Commodore Capital LP - MarketBeat
Terns Pharmaceuticals Financial Outlook Raises Concerns Amid Market Trends - timothysykes.com
Integral Health Asset Management LLC Grows Stock Holdings in Terns Pharmaceuticals, Inc. $TERN - MarketBeat
4 Biotech Stocks to Watch for Potential Upside in 2026 - The Globe and Mail
Terns Pharmaceuticals’ Valuation Reassessed Amid Latest Developments - StocksToTrade
Terns Pharmaceuticals (NASDAQ:TERN) Trading 4.8% HigherWhat's Next? - MarketBeat
Terns Pharmaceuticals CEO outlines strategy to advance novel leukemia therapy - Traders Union
Terns Pharmaceuticals shares rise as investors focus on recent presentation, index-addition notice, and upcoming earnings - Quiver Quantitative
Terns Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:TERN) - MarketBeat
Terning The Flight to Innovation with Terns Pharma - TD Securities
TERN: TERN-701 shows best-in-disease efficacy and safety in CML, with pivotal trials and launch funded - TradingView
Dynamic Technology Lab Private Ltd Grows Stock Position in Terns Pharmaceuticals, Inc. $TERN - MarketBeat
TERN: TERN-701 shows superior efficacy and safety in CML, positioning for major market impact - TradingView
DLD Asset Management LP Cuts Stake in Terns Pharmaceuticals, Inc. $TERN - MarketBeat
Will Terns Pharmaceuticals Inc. stock benefit from automation2026 Opening Moves & Safe Entry Momentum Tips - Naître et grandir
Wall Street analysts see a 50.91% upside in Terns Pharmaceuticals (TERN): Can the stock really move this high? - MSN
What is Terns Pharmaceuticals Incs debt to equity ratioWeekly Stock Report & Breakout Confirmation Trade Signals - baoquankhu1.vn
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing - The Globe and Mail
TERN Earnings History & Surprises | EPS & Revenue Results | TERNS PHARMACEUTICALS INC (NASDAQ:TERN) - ChartMill
TERN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Portfolio Update: How does Terns Pharmaceuticals Inc score in quality rankingsMarket Rally & Low Risk Entry Point Tips - baoquankhu1.vn
A Look At Terns Pharmaceuticals (TERN) Valuation After Leerink Highlights Early TERN-701 CML Data - Yahoo Finance
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):